Marine Sediment Recovered Salinispora sp. Inhibits the Growth of Emerging Bacterial Pathogens and other Multi-Drug-Resistant Bacteria
, , , , , , et
08 sept. 2020
À propos de cet article
Catégorie d'article: original-paper
Publié en ligne: 08 sept. 2020
Pages: 321 - 330
Reçu: 19 mars 2020
Accepté: 25 juil. 2020
DOI: https://doi.org/10.33073/pjm-2020-035
Mots clés
© 2020 Luis Contreras-Castro et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Fig. 1.

Fig. 2.

Fig. 3.

Characteristics of clinical isolates_
Clinical isolate | Source of infection | Antibiotic resistance |
---|---|---|
Corneal ulcer | Oxacillin, ofloxacin, tobramycin, cefalotin, ceftriaxone, sulfisoxazole | |
Corneal ulcer | Neomycin, gentamicin, ceftazidime, ceftriaxone, tetracycline, sulfisoxazole | |
Corneal ulcer | Norfloxacin, ceftazidime, ceftriaxone, polymyxin B, sulfisoxazole | |
Corneal ulcer | Gentamicin, ceftazidime, ceftriaxone, tetracycline, sulfisoxazole | |
Corneal ulcer | Norfloxacin, ceftazidime, ceftriaxone | |
Conjunctivitis | Ofloxacin, tobramycin, gentamicin, norfloxacin, cefalotin, ceftazidime, tetracycline, sulfisoxazole | |
Endophthalmitis | Oxacillin, tobramycin, gentamicin, ceftazidime, ceftriaxone, tetracycline | |
Endophthalmitis | Ofloxacin, tobramycin, gentamicin, norfloxacin, ceftazidime, ceftriaxone, polymyxin B, tetracycline, sulfisoxazole | |
Hip | Oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, rifampin, trimethoprim-sulfamethoxazole | |
Knee | Oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, rifampin, trimethoprim-sulfamethoxazole | |
Hip | Oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline | |
Hip | Oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, erythromycin, clindamycin | |
Hip | Oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, trimethoprim-sulfamethoxazole | |
Hip | Oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, trimethoprim-sulfamethoxazole | |
Hip | Oxacillin, ciprofloxacin, levofloxacin, moxifloxacin, clindamycin | |
Hip | Oxacillin, ciprofloxacin, levofloxacin, moxifloxacin | |
Hip | Oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, erythromycin, clindamycin | |
Hip | Oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin | |
Urine sample | Ceftazidime, ceftriaxone, cefepime, doripenem, etapenem, meropenem, | |
imipenem, amikacin, gentamicin, ciprofloxacin, rifamycin | ||
Wound infection | Ceftazidime, ceftriaxone, cefepime, doripenem, etapenem, meropenem, imipenem, amikacin, gentamicin, ciprofloxacin, rifamycin | |
Blood sample | Piperaciline, ceftazidime, ceftriaxone, cefepime, doripenem, etapenem, meropenem, imipenem, amikacin, gentamicin, ciprofloxacin, rifamycin | |
Blood sample | Piperaciline, ceftazidime, ceftriaxone, cefepime, doripenem, etapenem, meropenem, imipenem, amikacin, gentamicin, ciprofloxacin, rifamycin | |
Wound infection | Oxacillin, gentamicin, ciprofloxacin, erythromycin, clindamycin, tetracycline, trimethoprim-sulfamethoxazole, penicillin, rifamycin | |
Urine sample | Erythromycin, clindamycin, tetracycline, penicillin, rifamycin |
Primers for the MLSA amplification_
Gene | Primer sequence (5’-3’) | Product size (bp) | Reference |
---|---|---|---|
ATPDF2 – CTTGCGGTGYATSGACCA | 910 | Rong and Huang 2014 | |
ATPDR3 – GAAGAASGCCTGYTCNGG | |||
GYRBF – GAGGTCGTGCTGACCGTGCTGCACGCGGGCGGCAAGTTCGGC | 781 | ||
GYRBR – ATGGCGGACGCCGACGTCGACGGCCAGCACATCAAC | |||
MYCOF – GGYAAGGTCACSCCSAAGGG | 730 | ||
MYCOR – ARCGGCTGCTGGGTRATC | |||
SECYF – GGCATCATGCCCTACATCAC | 797 | Adekambi et al. 2011 | |
SECYR – AAACCGCCGTACTTCTTCAT |